Hikma’s Calculated Patience: Investing Through the Injectable Trough
Strong H1 numbers mask a deliberate investment push — management keeps guidance steady to fund R&D, CMO, and U.S. manufacturing ahead of a 2027 inflection.
HIK.L · Earnings Call · 2026-08-06
Half-Year Momentum Meets Full-Year Restraint
Hikma delivered a solid first half: sales up, EBIT up almost 8%, EPS up 5%, and the injectables business finally stable. Yet the company chose to leave full-year guidance unchanged — revenue growth of 2-4% and core operating profit of $720-770 million — even though first-half revenue already sits at the upper end of that range. The message is deliberate: management is tempering near-term expectations to fund a strategic reset. “EBIT and EBITDA are up by almost 8%. EPS is up by 5%. And what we -- when we met last time, we said we had like 4 targets this year. One is to stabilize the business.” — Said Darwazah, CEO · 2026-08-06 Stabilization is one thing; growth is another. The CEO announced that the injectable engine will start to fire next year, and the investments are already visible: R&D is up, safety stock is being rebuilt, and the supply chain is being overhauled. Safety stock is more than a balance-sheet line — it enables the company to seize shortage opportunities that were previously missed.The TYZAVAN Barometer
TYZAVAN, the ready-to-use vancomycin product, is the bellwether for the injectables strategy. Management is patient but confident: formularies are adopting, and monthly pickup is building toward an acceleration in Q4. “For TYZAVAN, it takes a long time for the formularies of the different buying groups do to take it on... So we have been seeing a pickup month by month, and we feel very comfortable that for the second of the half or the second half of this year that we will continue seeing this increase month by month.” — Said Darwazah, CEO · 2026-08-06 The product is also the foundation for a broader ready-to-use platform that should drive growth into 2028 and beyond. TYZAVAN is the first of several such products, and the sales team has more than tripled in size.Made in USA as a Strategic Moat
As tariff rhetoric swirls across the sector, Hikma is leaning into its domestic manufacturing footprint. The company is one of the largest U.S. producers of generics, with Rx business over 90% made in America. “I mean, on tariffs, we are one of the largest domestic manufacturers for generics in the U.S. So we feel that we are in a very strong position. We have invested a lot over the years in our U.S. manufacturing, and we continue to invest in U.S. manufacturing.” — Susan Ringdal, Acting CFO · 2026-08-06 Management has even secured $50 million in Ohio state incentives, underscoring its commitment to local production. This positioning could become a durable advantage as buyers and regulators push for supply-chain resilience. U.S. manufacturing is not just a cost center; it is being framed as a competitive differentiator.Capital Allocation and the CMO Push
The company is also simplifying its portfolio. The 503B compounding business is being divested, having been classified as held for sale. The buyback is nearly complete — over 11 million shares repurchased — and management is keeping powder dry for potential M&A, particularly in Europe where it sees attractive midterm targets and expansion opportunities. A big part of the future growth narrative is the contract manufacturing (CMO) business. The company is hiring a dedicated head of CMO and has major contracts ramping. CMO side is expected to contribute significantly to both Rx and injectables over the next few years. The message is coherent: Hikma is using the cushion of a strong H1 to invest aggressively in the capabilities that will drive growth from next year onward. As the CEO put it:The company's history of resilient growth across three engines supports the thesis. In a prior call, the leadership stressed the same logic: “We have 3 very strong divisions. Two of them are doing extremely well. The MENA is growing at a very fast rate with very good margins.” — Said Darwazah, Chief Executive Officer · 2026-02-26 “So of course, going forward, we are going to go back to return to very good growth for the injectable on top line and in terms of the EBIT.” — Khalid Nabilsi, Chief Operating Officer · 2026-02-26 For now, the market has to trust the roadmap. The guidance suggests H2 will see elevated spending, with revenue slightly lighter but EBIT weighted later in the year. That is the cost of building the next phase of growth. If TYZAVAN converts, the CMO pipeline delivers, and the R&D engine starts to churn, 2027 could be the inflection year Hikma has been promising.The drivers for growth, it's very simple. We always say it's not rocket science. Having the manufacturing machine being well established and having well-balanced lines... supply chain... safety stocks... R&D... and finally, acquisitions.